Perifosine: Updated Phase I/II data

Updated data from 73 evaluable patients with relapsed or refractory MM in a Phase I/II trial showed that perifosine plus Velcade bortezomib produced a 41% ORR. Median PFS was 6.4 months and median OS was 25 months. Of the 53 patients who were previously refractory to a Velcade-containing regimen, median PFS was 5.7 months and median OS was 22.5 months. Of the 20 patients who previously relapsed with a Velcade-containing regimen, median PFS was 8.8 months and median OS was not reached at 38 months. The trial enrolled 84 patients. Data were presented at the American Society of Hematology meeting in New Orleans. ...